Literature DB >> 26681393

Evaluation of Screening for Retinopathy of Prematurity by ROPtool or a Lay Reader.

Ashkan M Abbey1, Cagri G Besirli2, David C Musch3, Chris A Andrews2, Antonio Capone1, Kimberly A Drenser1, David K Wallace4, Susan Ostmo5, Michael Chiang6, Paul P Lee2, Michael T Trese7.   

Abstract

PURPOSE: To determine if (1) tortuosity assessment by a computer program (ROPtool, developed at the University of North Carolina, Chapel Hill, and Duke University, and licensed by FocusROP) that traces retinal blood vessels and (2) assessment by a lay reader are comparable with assessment by a panel of 3 retinopathy of prematurity (ROP) experts for remote clinical grading of vascular abnormalities such as plus disease.
DESIGN: Validity and reliability analysis of diagnostic tools. PARTICIPANTS: Three hundred thirty-five fundus images of prematurely born infants.
METHODS: Three hundred thirty-five fundus images of prematurely born infants were obtained by neonatal intensive care unit nurses. A panel of 3 ROP experts graded 84 images showing vascular dilatation, tortuosity, or both and 251 images showing no evidence of vascular abnormalities. These images were sent electronically to an experienced lay reader who independently graded them for vascular abnormalities. The images also were analyzed using the ROPtool, which assigns a numerical value to the level of vascular abnormality and tortuosity present in each of 4 quadrants or sectors. The ROPtool measurements of vascular abnormalities were graded and compared with expert panel grades with a receiver operating characteristic (ROC) curve. Grades between human readers were cross-tabulated. The area under the ROC curve was calculated for the ROPtool, and sensitivity and specificity were computed for the lay reader. MAIN OUTCOME MEASURES: Measurements of vascular abnormalities by ROPtool and grading of vascular abnormalities by 3 ROP experts and 1 experienced lay reader.
RESULTS: The ROC curve for ROPtool's tortuosity assessment had an area under the ROC curve of 0.917. Using a threshold value of 4.97 for the second most tortuous quadrant, ROPtool's sensitivity was 91% and its specificity was 82%. Lay reader sensitivity and specificity were 99% and 73%, respectively, and had high reliability (κ, 0.87) in repeated measurements.
CONCLUSIONS: ROPtool had very good accuracy for detection of vascular abnormalities suggestive of plus disease when compared with expert physician graders. The lay reader's results showed excellent sensitivity and good specificity when compared with those of the expert graders. These options for remote reading of images to detect vascular abnormalities deserve consideration in the quest to use telemedicine with remote reading for efficient delivery of high-quality care and to detect infants requiring bedside examination.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26681393     DOI: 10.1016/j.ophtha.2015.09.048

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

1.  Diagnostic Accuracy of Ophthalmoscopy vs Telemedicine in Examinations for Retinopathy of Prematurity.

Authors:  Hilal Biten; Travis K Redd; Chace Moleta; J Peter Campbell; Susan Ostmo; Karyn Jonas; R V Paul Chan; Michael F Chiang
Journal:  JAMA Ophthalmol       Date:  2018-05-01       Impact factor: 7.389

Review 2.  Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity.

Authors:  Dana Darwish; Ru-Ik Chee; Samir N Patel; Karyn Jonas; Susan Ostmo; J Peter Campbell; Michael F Chiang; R V Paul Chan
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2018-05-29

Review 3.  Plus Disease in Retinopathy of Prematurity: More Than Meets the ICROP?

Authors:  Layla Ghergherehchi; Sang Jin Kim; J Peter Campbell; Susan Ostmo; R V Paul Chan; Michael F Chiang
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2018-05-24

4.  Expert Diagnosis of Plus Disease in Retinopathy of Prematurity From Computer-Based Image Analysis.

Authors:  J Peter Campbell; Esra Ataer-Cansizoglu; Veronica Bolon-Canedo; Alican Bozkurt; Deniz Erdogmus; Jayashree Kalpathy-Cramer; Samir N Patel; James D Reynolds; Jason Horowitz; Kelly Hutcheson; Michael Shapiro; Michael X Repka; Phillip Ferrone; Kimberly Drenser; Maria Ana Martinez-Castellanos; Susan Ostmo; Karyn Jonas; R V Paul Chan; Michael F Chiang
Journal:  JAMA Ophthalmol       Date:  2016-06-01       Impact factor: 7.389

5.  Telemedicine for Retinopathy of Prematurity in 2020.

Authors:  Theodore Bowe; Cindy Ung; J Peter Campbell; Yoshihiro Yonekawa
Journal:  J Vitreoretin Dis       Date:  2019-09-05

6.  Teleophthalmic Approach for Detection of Corneal Diseases: Accuracy and Reliability.

Authors:  Maria A Woodward; David C Musch; Christopher T Hood; Jonathan B Greene; Leslie M Niziol; V Swetha E Jeganathan; Paul P Lee
Journal:  Cornea       Date:  2017-10       Impact factor: 2.651

Review 7.  Imaging in Retinopathy of Prematurity.

Authors:  N Valikodath; E Cole; M F Chiang; J P Campbell; R V P Chan
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Mar-Apr

Review 8.  Advances in understanding and management of retinopathy of prematurity.

Authors:  Mary Elizabeth Hartnett
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

9.  Retinopathy of Prematurity: Imaging in retinopathy of prematurity: where are we, and where are we going?

Authors:  Michael F Chiang
Journal:  J AAPOS       Date:  2016-11-03       Impact factor: 1.220

10.  Plus Disease in Retinopathy of Prematurity: Improving Diagnosis by Ranking Disease Severity and Using Quantitative Image Analysis.

Authors:  Jayashree Kalpathy-Cramer; J Peter Campbell; Deniz Erdogmus; Peng Tian; Dharanish Kedarisetti; Chace Moleta; James D Reynolds; Kelly Hutcheson; Michael J Shapiro; Michael X Repka; Philip Ferrone; Kimberly Drenser; Jason Horowitz; Kemal Sonmez; Ryan Swan; Susan Ostmo; Karyn E Jonas; R V Paul Chan; Michael F Chiang
Journal:  Ophthalmology       Date:  2016-08-24       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.